Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-09 11:33 am Purchase | 2021-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | STATE STREET CORP STT | 8,249,029 4.580% | 940,213 (+12.86%) | Filing History |
| 2022-02-01 5:08 pm Sale | 2021-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | BlackRock Inc. BLK | 14,787,395 8.200% | -1,472,350 (-9.06%) | Filing History |
| 2021-04-12 09:36 am Sale | 2021-03-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | STATE STREET CORP STT | 7,308,816 4.130% | -3,748,163 (-33.90%) | Filing History |
| 2021-02-16 4:53 pm Purchase | 2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | Baker Bros. Advisors LP | 18,178,881 9.990% | 2,303,756 (+14.51%) | Filing History |
| 2021-02-16 4:30 pm Sale | 2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | Citadel Advisors LLC | 6,660,717 3.800% | -2,234,718 (-25.12%) | Filing History |
| 2021-02-16 3:16 pm Sale | 2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | Point72 Asset Management, L.P. | 3,691,632 2.100% | -4,696,422 (-55.99%) | Filing History |
| 2021-02-11 12:54 pm Sale | 2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | JANUS HENDERSON GROUP PLC JHG | 0 0.000% | -9,408,481 (Position Closed) | Filing History |
| 2021-02-10 4:28 pm Sale | 2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | Integrated Core Strategies (US) LLC | 286,632 0.200% | -9,688,845 (-97.13%) | Filing History |
| 2021-02-10 10:39 am Purchase | 2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | The Vanguard Group | 11,599,334 6.570% | 3,477,703 (+42.82%) | Filing History |
| 2021-02-05 11:42 am Sale | 2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | STATE STREET CORP STT | 11,056,979 6.260% | -6,896,891 (-38.41%) | Filing History |
| 2021-01-28 5:56 pm Purchase | 2020-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | BlackRock Inc. BLK | 16,259,745 9.200% | 4,109,534 (+33.82%) | Filing History |
| 2021-01-25 4:43 pm Purchase | 2021-01-15 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | Sarissa Capital Management LP | 8,844,000 5.000% | 8,844,000 (New Position) | Filing History |